Aligos Therapeutics ALGS Stock
Aligos Therapeutics Price Chart
Aligos Therapeutics ALGS Financial and Trading Overview
| Aligos Therapeutics stock price | 5.22 USD |
| Previous Close | 5.33 USD |
| Open | 5.39 USD |
| Bid | 3.84 USD x 200 |
| Ask | 6.7 USD x 200 |
| Day's Range | 5.14 - 5.5 USD |
| 52 Week Range | 3.98 - 13.69 USD |
| Volume | 36.91K USD |
| Avg. Volume | 170.24K USD |
| Market Cap | 32.6M USD |
| Beta (5Y Monthly) | 2.333 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.71 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 53.43 USD |
ALGS Valuation Measures
| Enterprise Value | 5.72M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.0328453 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.0342214 |
| Price/Book (mrq) | 1.0211267 |
| Enterprise Value/Revenue | 0.181 |
| Enterprise Value/EBITDA | -0.073 |
Trading Information
Aligos Therapeutics Stock Price History
| Beta (5Y Monthly) | 2.333 |
| 52-Week Change | -43.11% |
| S&P500 52-Week Change | 15.30% |
| 52 Week High | 13.69 USD |
| 52 Week Low | 3.98 USD |
| 50-Day Moving Average | 5.92 USD |
| 200-Day Moving Average | 7.1 USD |
ALGS Share Statistics
| Avg. Volume (3 month) | 170.24K USD |
| Avg. Daily Volume (10-Days) | 58K USD |
| Shares Outstanding | 5.44M |
| Float | 3.7M |
| Short Ratio | 4.85 |
| % Held by Insiders | 10.64% |
| % Held by Institutions | 45.64% |
| Shares Short | 648.57K |
| Short % of Float | 12.22% |
| Short % of Shares Outstanding | 10.39% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:25 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -241.010% |
| Operating Margin (ttm) | -6.80% |
| Gross Margin | -180.40% |
| EBITDA Margin | -247.21% |
Management Effectiveness
| Return on Assets (ttm) | -49.11% |
| Return on Equity (ttm) | -113.58% |
Income Statement
| Revenue (ttm) | 31.52M USD |
| Revenue Per Share (ttm) | 3.03 USD |
| Quarterly Revenue Growth (yoy) | 2778.50% |
| Gross Profit (ttm) | -56859000 USD |
| EBITDA | -77916000 USD |
| Net Income Avi to Common (ttm) | -75962000 USD |
| Diluted EPS (ttm) | -7.65 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 30.38M USD |
| Total Cash Per Share (mrq) | 4.87 USD |
| Total Debt (mrq) | 3.5M USD |
| Total Debt/Equity (mrq) | 10.99 USD |
| Current Ratio (mrq) | 2.192 |
| Book Value Per Share (mrq) | 5.112 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -94168000 USD |
| Levered Free Cash Flow (ttm) | -61390248 USD |
Profile of Aligos Therapeutics
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | One Corporate Drive |
| ZIP | 94080 |
| Phone | 800 466 6059 |
| Website | https://www.aligos.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 82 |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Q&A For Aligos Therapeutics Stock
What is a current ALGS stock price?
Aligos Therapeutics ALGS stock price today per share is 5.22 USD.
How to purchase Aligos Therapeutics stock?
You can buy ALGS shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aligos Therapeutics?
The stock symbol or ticker of Aligos Therapeutics is ALGS.
Which industry does the Aligos Therapeutics company belong to?
The Aligos Therapeutics industry is Biotechnology.
How many shares does Aligos Therapeutics have in circulation?
The max supply of Aligos Therapeutics shares is 6.24M.
What is Aligos Therapeutics Price to Earnings Ratio (PE Ratio)?
Aligos Therapeutics PE Ratio is now.
What was Aligos Therapeutics earnings per share over the trailing 12 months (TTM)?
Aligos Therapeutics EPS is -7.71 USD over the trailing 12 months.
Which sector does the Aligos Therapeutics company belong to?
The Aligos Therapeutics sector is Healthcare.
Aligos Therapeutics ALGS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26333.04 USD — |
+0.96
|
5.66B USD — | 26283.11 USD — | 26431.22 USD — | — - | 5.66B USD — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12940.54 USD — |
+0.98
|
— — | 12913.4 USD — | 12988.37 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6924.69 USD — |
+0.05
|
— — | 6924.47 USD — | 7006.06 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1293.65 USD — |
+0.07
|
— — | 1293.64 USD — | 1310.12 USD — | — - | — — |
- {{ link.label }} {{link}}
